Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7780936 | 0.85 | HDAC1 (0.46) | HDAC1HDAC8HDAC6KMT2APOLB | |
| SCHEMBL29086028 | 0.85 | HDAC1 (0.43) | HDAC1HDAC8HDAC6KMT2APOLB | |
| SCHEMBL7782731 | 0.85 | HDAC1 (0.46) | HDAC1HDAC8HDAC6KMT2APOLB | |
| SCHEMBL7779876 | 0.85 | HDAC1 (0.46) | HDAC1HDAC8HDAC6KMT2APOLB | |
| SCHEMBL7779878 | 0.85 | HDAC1 (0.46) | HDAC1HDAC8HDAC6KMT2APOLB | |
| SCHEMBL7775653 | 0.85 | HDAC1 (0.46) | HDAC1HDAC8HDAC6KMT2APOLB | |
| SCHEMBL13359888 | 0.84 | HDAC1 (0.44) | HDAC1HDAC8HDAC6KMT2APOLB | |
| SCHEMBL17138602 | 0.81 | ELANE (0.46) | HDAC1HDAC8HDAC6KMT2APOLB | |
| SCHEMBL585894 | 0.80 | APP (0.45) | HDAC1HDAC8HDAC6KMT2APOLB | |
| SCHEMBL27845692 | 0.80 | APP (0.45) | HDAC1HDAC8HDAC6KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713965-B2 | 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2010-05-11 | — | — | US | disclosed |
| US-20090221565-A1 | NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221565-A1 | NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | CBR3, CBR1, TECR | HDAC1 1758/4885HDAC8 1486/4885HDAC6 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.